The world's dedicated summit series at the intersection of Immuno-Oncology and Biomarker Discovery uniting global leaders across London and Boston.
Two independent editions per year, each tailored to its regional scientific community.
ImmunoMark Summit London
ImmunoMark Summit Boston
ImmunoMark Summit London
The only conference series dedicated to the intersection of Immuno-Oncology and Biomarker science.
Two fully independent parallel tracks - Immuno-Oncology and Biomarkers & CDx - for in-depth, targeted learning.
45-50% of attendees are C-suite, VPs, and Directors from pharma, biotech, and diagnostics companies globally.
Structured 1:1 meetings, panel discussions, and a Gala Dinner designed for meaningful strategic connections.
London and Boston - the world's leading centres for oncology drug development and biotech innovation.
Programs bridge bench science with regulatory, clinical, and commercialization strategy - relevant to all stakeholders.
Experts from AstraZeneca, Roche, Merck, J&J, Novartis, GSK, Oxford, and more - setting the scientific standard.
Companies who sponsor ImmunoMark to reach the world's most concentrated audience of oncology decision-makers.
ImmunoMark Summit delivers actionable discussions that go beyond theory - bridging clinical research, regulatory strategy, and commercial impact.
Sponsors consistently highlight the quality of speakers, curated networking, and the depth of scientific exchange that sets this summit apart.
400+ senior leaders. Two streams. One agenda: advancing precision oncology.
Register for Boston Edition
